Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilars Forum Welcomes PBM Transparency Act

US Proposals Would See Spread Pricing Outlawed And Rebates Disclosed

Executive Summary

Senators Maria Cantwell and Chuck Grassley have introduced a bill which would limit pharmacy benefit managers’ ability to engage in “unfair and deceptive” business practices, a move which has been welcomed by the Biosimilars Forum.

You may also be interested in...



US Biosimilars Need Access In Exchange For Industry Commitment

As the dust settles after a wave of fresh adalimumab biosimilar launches, the US Biosimilars Forum’s executive director Julie Reed talks to Generics Bulletin about how other stakeholders need to step up to meet industry’s commitment to the sector – as well as how PBMs are distorting the market and streamlined regulation is needed to drive competition.

Express Scripts Unveils New Co-Pay Cap For Generics Amid PBM Scrutiny

Cigna’s PBM, Express Scripts, is looking to “further align incentives across the pharmaceutical supply chain, consumers, and clients,” with a trio of new products available starting this summer.

AAM Condemns ‘Build Back Better 2.0’ Due To Off-Patent Impact

The Association for Accessible Medicines has criticized draft legislation regarding US drug pricing negotiations for the impact proposed new laws could have on generic and biosimilar drugs.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB151988

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel